Per diffusione immediata - 20 gennaio 2010

Seneffe, Belgio, 20 gennaio 2010 - IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) ? stata informata della decisione della 18a camera della Corte d'appello di Bruxelles relativa alle controversie tra Eckert & Ziegler AG (EZAG) e SMI Steligtz (SMI), da un lato, e a un azionista minoritario di IBt Bebig (Creafund II) e alla Commission Bancaire, Financi?re et des Assurances (Commissione bancaria, finanziaria e assicurativa, CBFA) dall'altro.

La sentenza della Corte d'appello (comune alle tre vertenze in corso) stabilisce, in sintesi, quanto segue:

- The court has confirmed the CBFA orders of April 28 and May 27, 2009 stating that EZAG and SMI should be deemed "persons acting in concert" and that, because their ownership of IBt common stock exceeded 30 percent as of January 26, 2009, they are required to make a joint and several takeover offer.

- The court has sided with Creafund II in its suit to compel EZAG and SMI to launch a mandatory takeover bid and to pay damages.

- The court has ordered EZAG and SMI to pay damages and legal costs.

The court points out that, the suits have become largely meaningless in practice, since a takeover offer has been initiated. The full text of the Brussels Court of Appeals decision, issued on January 19, 2010, will be available on the IBt website this morning:

http://www.ibt-bebig.eu/en/sidenavigation/press/press_releases.html

About IBt Bebig

... Contributing to saving lives!

The IBt Bebig group is a European based group, active in the Medical Device segment of the Health Care sector.

The core business of the IBt Bebig group is the cancer treatment by radiation technology. Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis. Depending on the application, the implant can take the shape of a plaque, a seed or a catheter. The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient's quality of life. Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers.

The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India. Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH.BR - Bloomberg : IBTB BB).

Contact

Paul-Emmanuel Goethals
Head of Investor Relations & Communication
Tel: +32.64.520.808

E-mail: ir@ibt-bebig.eu
Internet: www.ibt-bebig.eu

Copyright Hugin

Questo comunicato ? distribuito da Hugin. L'emittente ? l'unico responsabile per il contenuto del comunicato.

[CN#162303]